We're excited to announce a new partnership with WeComput to enhance Innovent Academy's Computing Platform for faster, AI-driven drug discovery. We're using WeComput's WeMol platform to upgrade our R&D capabilities with advanced molecular design, along with NVIDIA's #BioNeMo to boost computing for developing new healthcare solutions. https://lnkd.in/gsCxtj7c #InnoventBiologics #HealthCare
Innovent Biologics
Pharmaceutical Manufacturing
Suzhou, Jiangsu 21,995 followers
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people
About us
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases such as cancer. On 31 October, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 5 assets in Phase III or pivotal clinical trials, and additional 14 molecules in to clinical trials. TYVYT® was included in the National Reimbursement Drug List (NRDL) in 2019 as the only PD-1 in that year and was also the first PD-1 inhibitor included in NRDL historically. Innovent has built a biopharmaceutical production facility that operates under global standards. The design and operation of the clinical and commercial facilities are in compliance with the cGMP standards of NMPA, FDA and EMA. The existing production lines have already passed GMP audits by an international pharmaceutical company. Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic cooperation with Eli Lilly, Adimab, Incyte, Hanmi and other international pharmaceutical companies.
- Website
-
http://www.innoventbio.com
External link for Innovent Biologics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Suzhou, Jiangsu
- Type
- Public Company
- Founded
- 2011
- Specialties
- Biologics Manufacturing, Monoclonal Antibodies, Biosimilars, and Novel Drugs
Locations
Employees at Innovent Biologics
-
Stephen Lau
Biotech C-Suite Executive and Board Member | Entrepreneur | Focused on Fundraising & Deal-making | Company Formation | Passionate about Many Things…
-
Wenli Zhao
-
Jia Duo
Sr. Director at Innovent Biologics（信达生物制药）
-
Blake Salisbury
Senior Vice President of Business Development at Innovent Biologics
Updates
-
We are proud to announce that DREAMS-1, our Phase 3 clinical trial of mazdutide in Chinese adults with type 2 diabetes (T2D) met primary and key secondary endpoints! With DREAMS-2 for the treatment of T2D also achieving its study goals, we’re preparing to submit another NDA for mazdutide to China’s NMPA, marking a significant step in advancing diabetes treatment. #InnoventBiologics #Mazdutide https://lnkd.in/geJcm_ci
-
-
Our new ESG website is live! At Innovent, our mission to empower patients worldwide with affordable, high-quality biopharmaceuticals drives us to integrate ESG principles into every aspect of our value chain. We are dedicated to ensuring the highest quality in our products, while also caring for our people and the environment. Discover more about our commitment to Environmental, Social and Governance (ESG) initiatives on our newly launched website: https://lnkd.in/gzQrv-gW #ESG #Sustainability #Healthcare #InnoventBiologics
-
-
We are thrilled to announce that Innovent has been recognized in Universum's "2024 China's Most Attractive Employers Rankings"! 🏅 10th Position as the Most Attractive Employer for natural science students 🏅 19th Position as the Most Attractive Employer for health/medicine students 🏅 Top 100 Most Attractive Employers for engineering students This achievement highlights our commitment to innovation, mentorship, excellence in cutting-edge research and therapies, strong corporate social responsibility and our inspiring mission and vision. We're grateful to our incredible team and community for making this possible. Together, we are creating a supportive workplace, prioritizing employee wellness, and inspiring our team to make a positive difference in healthcare. #InnoventBiologics #Healthcare #Universum2024
-
-
Our team had the incredible opportunity to give an oral presentation at ESMO GI in Munich. We shared the latest Phase 1 clinical data of our innovative anti-CLDN18.2 ADC, IBI343, for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJ AC). The results demonstrate that IBI343 has promising efficacy and a favorable safety profile in patients with G/GEJ AC whose tumors express CLDN18.2. We’re proud to be pushing the boundaries of cancer treatment and improving patient outcomes. https://lnkd.in/gujfiyyv #ESMOGI2024 #ClinicalTrials #InnoventBiologics #Oncology
-
-
At #ADA2024 and during our recent investor call, Innovent presented the promising results of the GLORY-1 Phase 3 clinical trial for the GLP-1R/GCGR dual agonist mazdutide, along with updates on our general biomedicine pipeline. See the exciting results here:https://lnkd.in/gPrQhh8S
-
-
We're especially thrilled to share the GLORY-1 Phase 3 study results of liver fat content in Chinese adults with overweight or obesity at the #ADA Scientific Sessions 2024. This clinical trial of mazdutide brings us closer to offering improved treatment options for those with metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated fatty liver disease (MAFLD). https://lnkd.in/gdXTAxKp
-
-
Exciting news from the ADA Scientific Sessions 2024! Our team presented the key results from the first Phase 3 clinical trial of the GLP-1R/GCGR dual agonist mazdutide in Chinese adults with overweight or obesity, where GLORY-1 met all primary and key secondary endpoints, showcasing robust weight loss, reduced liver fat content, and improvements in multiple cardiometabolic risk factors. https://lnkd.in/gtzSRyC6 #ADA2024 #InnoventBiologics
-
-
We’re glad to share the positive data from our oncology pipeline update at today's investor meeting. Encouraged by the progress we're making in cancer treatment. https://lnkd.in/gtE7VKYu #Oncology #innoventbiologics
-
-
We are pleased to invite investors, analysts and stakeholders to participate in our conference call on June 25, highlighting clinical updates from our general biomedicine product line. Registration required at the link below. https://lnkd.in/gcgmSBv6
-